Colon cancer test points to most effective treatments

November 29, 2001

Cancer researchers have added a valuable tool to oncologists' tumor-fighting toolbox: a way to find more effective medicines to give advanced colon cancer patients after their first round of chemotherapy failed.

Just by analyzing tissue from a patient's tumor, research oncologists at the USC/Norris Comprehensive Cancer Center can predict whether a patient is likely to respond to treatment that combines one of the world's most-prescribed anti-cancer drugs and a powerful platinum-based chemotherapy.

Oncologist Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of the University of Southern California, reported the findings in the Dec. 1 issue of the Journal of Clinical Oncology. The results mean physicians can better customize treatment for metastatic colon cancer patients and steer them toward medicines that hold the greatest potential for extending patients' lives.

"For the first time, we are finding markers that identify the success of second-line therapy," says Lenz, scientific director of cancer genetics at USC/Norris. "We can predict who will respond to this therapy, while sparing others the discomfort of a therapy that probably would not help them."

Lenz and his team studied tumor response and patient survival using chemotherapy combining oxaliplatin and 5-FU, or fluorouracil. Oxaliplatin is an investigational platinum compound and 5-FU is a longstanding drug used to battle many cancers. The team is the first to look at such tumor testing and patient outcome with oxaliplatin.

The study included 50 patients with advanced colorectal cancer. Patients had already failed at least one prior chemotherapy regimen before oncologists placed them on 5-FU and oxaliplatin.

Researchers analyzed tissue from participants' surgically removed tumors to see how much of two key enzymes the tumors expressed. Those amounts can vary from patient to patient, depending on genes.

In this case, Lenz and colleagues looked at two key genetic players: the excision repair cross-complementing gene 1, known as ERCC1 for short, and the thymidylate synthase, or TS, gene.

In a healthy person, ERCC1 helps repair routinely damaged genetic material in cells, and TS helps reproduce this genetic material. Unfortunately, though, cancerous tumor cells use the enzymes, too. They can feed off the TS to reproduce their own DNA, and use ERCC1 to fix the DNA that chemotherapy is meant to damage.

This is important for cancer patients, Lenz explains, because it appears the more their tumors' genes can make the enzymes, the more their tumors can resist certain chemotherapy drugs.

By testing tumor tissue samples through a unique technology, the USC/Norris researchers determined exactly how much of the enzymes each patient's tumor produced.

They found that patients with low TS and low ERCC1 expression survived a median of 336 days after starting the 5-FU and oxaliplatin chemotherapy--more than three times longer than the median 95 days survived by patient with tumors that expressed high levels of TS or ERCC1.

So oxaliplatin and 5-FU therapy is indeed more effective for patients with low TS and ERCC1 expression, Lenz concludes. If patients can be tested for these characteristics before starting treatment, doctors can make sure they give oxaliplatin and 5-FU to patients most likely to benefit--and spare others uncomfortable chemotherapy that would not be of much help.

It also could point physicians to try other drugs for these patients.

"We now need to test whether these patients who would not do well with oxaliplatin should be treated with alternative therapies," Lenz says. USC/Norris is now a site for a clinical trial of an investigational drug called TLK 286, which appears to work well against tumors that are resistant to oxaliplatin. And another new drug, known as NB 1011, actually focuses on tumor cells that express high levels of TS.

In the future, the USC/Norris team will conduct similar tests with other genes responsible for repairing DNA and other markers that may predict whether tumors will respond to standard and investigational chemotherapies. They also will examine such markers in different types of cancer.

Finding out more about these markers may also help researchers develop more targeted anti-cancer drugs.

The need for more customized, effective therapy is clear: Colorectal cancer is the third most common cancer in the United States, and experts expect 130,000 new cases to be diagnosed this year. Unfortunately, the five-year survival rate for patients with advanced or metastatic disease is less than 10 percent.
-end-
Yoshinori Shirota, Jan Stoehlmacher, Jan Brabender, Yi-Ping Xiong, Kathleen D. Danenberg, Susan Groshen, Denise D. Tsao-Wei, Peter V. Danenberg, Heinz-Josef Lenz. "ERCC1 mRNA Levels and Thymidylate Synthase (TS) mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy" Journal of Clinical Oncology, Dec. 1, 2001, Vol. 19, No. 23.

University of Southern California

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.